|
GB201908780D0
|
|
Melanoma biomarkers
|
|
WO2019115480A1
|
|
Melanoma checkpoint inhibitor detection and treatment
|
|
WO2018234577A1
|
|
Immuno-oncology for the treatment of cancer
|
|
US2019120834A1
|
|
Marker sequences for rheumatoid arthritis
|
|
EP3258268A1
|
|
Marker sequences for managing treatment of patients suffering from rheumatoid arthritis
|
|
WO2016005295A1
|
|
Marker sequences for diagnosing and stratifying systemic sclerosis patients
|
|
WO2015169973A2
|
|
Marker sequences for diagnosing and stratifying systemic sclerosis patients
|
|
US2015177247A1
|
|
Method for identifying marker sequences for gynaecological malignant tumours
|
|
WO2015118184A1
|
|
Marker sequences for diagnosing and stratifying sle patients
|
|
EP2979094A1
|
|
Method for the diagnosis of neuromyelitis optica
|
|
WO2013170994A1
|
|
Marker sequences for rheumatoid arthritis
|
|
EP2735875A1
|
|
Marker sequences for Neuromyelitis Optica (NMO) and use thereof
|
|
US2014371095A1
|
|
Novel method for identifying specific marker sequences for prostate cancer
|
|
EP2745115A1
|
|
Novel method for diagnosis of high-affinity binders and marker sequences
|
|
EP2644704A1
|
|
Marker sequences for rheumatoid arthritis
|
|
EP2607900A1
|
|
Marker sequences for breast cancer and use of same
|
|
EP2605017A1
|
|
Marker sequences for gynaecological malignoma and use of same
|
|
EP2487251A1
|
|
Marker sequences for the diagnosis of prostate carcinoma and use of same
|
|
EP2441848A1
|
|
Marker sequences for systematic lupus erythematodes and use of same
|
|
DE102010042359A1
|
|
Marker sequences for multiple sclerosis and their use
|
